Myriad Genetics set to launch CardiaRisk genetic test for high blood pressure in January.
This article was originally published in The Gray Sheet
Executive Summary
MYRIAD GENETICS' CARDIARISK GENETIC HIGH BLOOD PRESSURE TEST LAUNCH is on track for mid-January, according to the company. Used to identify patients with hypertension who have a genetic variant that makes them particularly sensitive to sodium and who are at risk of heart disease, kidney failure and stroke, the test will be marketed to physicians via an outside sales force at a price of $300-400, the firm says.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.